AI Summary
✦ ClarthaValuation Metrics
Trading 20.5% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -1.79). Confidence: 89%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
34.17
Current
26.04
Overvalued
35.76
Undervalued
29.62
5Y Average
25.69
Current
19.80
Overvalued
27.84
Undervalued
22.39
5Y Average
3.93
Current
3.03
Overvalued
4.52
Undervalued
3.34
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
JEENA SIKHO LIFECARE LTD JSLLPharmaceuticals | +28.8% | 27.8% | 30.3x Fair | 0% vs avg | +11.6% |
AMRUTAJAN HEALTH LTD trades in line with peers (26.3x vs avg 30.3x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include JEENA SIKHO LIFECARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹150 CrMar 2026Latest net profit
₹16 CrMar 2026Latest EPS
₹5.60Mar 2026Net margin
17.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 100 | 78 | 99 | 117 | 127 | 84 | 110 | 123 | 135 | 94 | 118 | 141 | 150 |
| Expenses + | 87 | 71 | 92 | 95 | 111 | 80 | 96 | 99 | 118 | 86 | 101 | 116 | 124 |
| Operating Profit | 13 | 7 | 7 | 22 | 16 | 4 | 14 | 23 | 18 | 8 | 17 | 25 | 26 |
| OPM % | 13% | 9% | 7% | 18% | 13% | 4.2% | 12% | 19% | 13% | 9% | 14% | 18% | 17% |
| Other Income + | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | -3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 16 | 9 | 9 | 24 | 20 | 6 | 16 | 26 | 21 | 11 | 19 | 26 | 21 |
| Tax % | 23% | 26% | 26% | 26% | 30% | 27% | 26% | 26% | 27% | 26% | 27% | 26% | 23% |
| Net Profit + | 13 | 7 | 7 | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 | 19 | 16 |
| EPS in Rs | 4.34 | 2.40 | 2.37 | 6.04 | 4.72 | 1.60 | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.60 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015,
Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results For The Quarter Ended 30Th June 2026